COPD (Chronic Obstructive Pulmonary Disease) expected to become world's fifth ranked burden of disease by 2020

ข่าวทั่วไป Tuesday December 11, 2001 16:30 —PRESS RELEASE LOCAL

Bangkok--Dec 11--Weber Shandwick Thailand
SILENT KILLER REMAINS UNKNOWN TO MANY
COPD (Chronic Obstructive Pulmonary Disease) expected to become world's fifth ranked burden of disease by 2020
It is estimated that 2.74 million people worldwide died of Chronic Obstructive Pulmonary Disease (COPD) in year 2000, and as a single cause of death the disease shares fourth and fifth place with HIV/AIDS, after coronary heart disease, cerebrovascular disease and acute respiratory infection.
The prevalence of COPD in the Asia Pacific region and strategies for managing the burden of this disease were key issues discussed at a recent regional conference held in Hong Kong over the weekend (December 8 and 9, 2001). Sponsored by Boehringer Ingelheim, a leading global provider of respiratory care, the conference - COPD Today: Bringing New Life into a Global Problem - brought together respiratory experts from within and beyond the Asia Pacific region to explore ways to better diagnose and manage COPD.
The prevalence of COPD and its potential to rise by alarming rates is due largely to a lack of awareness of the existence of this disease, as its symptoms are often mistaken for other respiratory ailments like asthma, emphysema and bronchitis.
What is COPD? COPD is a chronic respiratory disorder that progressively worsens lung function and limits airflow. Its symptoms include shortness of breath, coughing, wheezing and increased sputum production. The disease progresses with age, leading to disability to perform usual daily activities and early death.
According to the Annual World Health Report of the WHO, about 600 million people suffer from COPD. While smoking is the main cause of COPD, with up to 90 per cent of all COPD patients being smokers, passive exposure to cigarette smoke, and exposure to severe air pollution also contribute to the development of COPD.
COPD in Asia Pacific Alarmingly, the disease is likely to become a significant problem in Asia Pacific countries, according to a study unveiled at the Hong Kong COPD conference. The study investigated the prevalence of COPD in 12 Asia Pacific countries , and estimated that on average, moderate to severe cases of COPD afflicts 6.3 per cent of the region's population.
"This is considerably higher than the rate of 3.9 per cent initially estimated by the World Health Organization," said Professor Paul Seale, the Pro-Dean of the Faculty of Medicine at the University of Sydney, Australia. "Whereas other global diseases like tuberculosis and HIV are predicted to decline over the next 20 years, the incidence of COPD is expected to increase," he added.
Professor Mary Ip, an Associate Dean with the Faculty of Medicine at the University of Hong Kong, said that the main challenge to managing COPD in Asia Pacific is getting both governments and communities to recognize the importance of reducing the main causes of the disease, such as smoking, and getting people to recognize the disease and seek early treatment.
"The support of the various health authorities and the medical fraternity is critical to these endeavors. Given the size of the region's population as a whole, particularly countries which have the highest prevalence of smoking in the world, and the chronic and debilitating nature of this disease, Asia is highly vulnerable to a substantial healthcare burden from COPD," said Profession Ip.
A World Bank/World Health Organisation study ranked this relatively unknown killer as the 12th burden of disease in 1990, and is expected to rise to the 5th ranked burden of disease by the year 2020.
Global (and Regional) Initiatives to Manage COPD In an effort to ensure COPD gets adequate attention from the healthcare communities and governments, there have been a number of national and international guidelines aimed to improve the diagnosis, management and prevention of COPD.
The Global initiative for chronic Obstructive Lung Disease (GOLD), which involved collaboration between the WHO, the US National Heart, Lung and Blood Institute, and an international team of experts, is one such global project to boost worldwide awareness of COPD and decrease the morbidity and mortality it causes. GOLD aims at facilitating the implementation of evidence-based recommendations in countries to help achieve a high and consistent standard of care for patients with COPD.
Presenting the Asia Pacific perspective to the GOLD guidelines at the Hong Kong conference, Professor Wan-Cheng Tan, a professor of Medicine at the National University of Singapore, said: "We want to engage the medical fraternity and pharmaceutical corporations to co-ordinate and sustain efforts to implement these global standards at the regional and individual country level. The ultimate aim is to prevent disease progression, relieve symptoms, prevent and treat complications, and reduce mortality."
Pharmaceutical firms like Boehringer Ingelheim have also been working closely with international health bodies and the medical fraternity to raise awareness of the disease. The company has helped set up respiratory centers in Philippines, Thailand and Vietnam to properly diagnose and treat COPD, as well as other respiratory ailments like asthma.
To find out more about COPD, consumers can log on to www.copdeducation.org, and medical professionals may go to www.copdprofessional.org.
NOTE TO EDITORS For further information on papers presented at the COPD conference, or if you/your writer is interested in speaking to the conference speakers or to relevant local experts, we will be happy to facilitate this.
ABOUT BOEHRINGER INGELHEIM Boehringer Ingelheim has for a long time been in the forefront of treatment and research of COPD with its inhaled anticholinergic bronchodilators, which are recommended in the first-line of maintenance treatment for COPD by many guidelines. As COPD is underdiagnosed and undertreated, Boehringer Ingelheim has campaigned to raise awareness and understanding of COPD worldwide. It has widely supported COPD research, development and implementation of COPD guidelines, patient and medical education in COPD, public awareness campaigns for COPD etc. An important feature of these activities has been close partnership with healthcare organisations.
The Boehringer Ingelheim group of companies, headquartered in Ingelheim (Germany) is one of the 20 leading pharmaceutical corporations in the world. In 2000, it reported revenues of almost EUR 6 billion in 2000.
Boehringer Ingelheim has world wide some 140 affiliated companies. The focus is on the human pharmaceutical as well as on the animal health business. The human pharmaceutical business which is responsible for 95% of sales, includes mainly prescription medicines and products for consumer health care but also for industrial customers (chemicals and biopharmaceuticals).
Substantial research and development, production, and distribution facilities are located around the globe. In 2000 Boehringer Ingelheim spent EUR 1.0 billion on R&D, equivalent to 16% of total sales.
For more information on Boehringer Ingelheim please see also the international Internet website www.boehringer-ingelheim.com
For more information:
Kanticha Boonpokaew
Weber Shandwick Thailand for Boehringer Ingelheim
Tel: +662-257-0300 ext. 333
Fax: +662-257-0312-13
Email: [email protected]
Pensri Tasnavites
Weber Shandwick Thailand for Boehringer Ingelheim
Tel: +662-257-0300 ext. 330
Fax: +662-257-0312-13
Email: [email protected] End.
-SS-

แท็ก the nation   World Bank   thailand   Bangkok   ESSO   TOT  

เว็บไซต์นี้มีการใช้งานคุกกี้ ศึกษารายละเอียดเพิ่มเติมได้ที่ นโยบายความเป็นส่วนตัว และ ข้อตกลงการใช้บริการ รับทราบ